Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Publication year range
1.
Int J Low Extrem Wounds ; 15(2): 148-54, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27009790

ABSTRACT

The aim of this study was to document the profile of pyoderma gangrenosum (PG) patients who were treated in our clinic and to compare our patients' clinical and demographic characteristics with those described in the literature to help our understanding of the total burden of PG. A total of 27 (17 women, 10 men) patients with a mean age 48.6 years at diagnosis were included in the study. Seven (25.9%) of them had 3 or more ulcers. The lower extremity was the most common site of occurrence (92.5%). During the study period, 6 patients were admitted twice, and 7 were admitted 3 or more times (range 1 to >10), and the median length of stay was 27 days. A concomitant disease was present in PG patients especially in those between 20 and 40 years of age. Systemic therapy was used in 21 (91.3%) patients, 17 patients were treated with systemic corticosteroids, either alone in 7 patients or combination with other agents in 10 patients. Three of our patients died because of disease or treatment-related complications during the study period. Despite the high (70.3%) percentage of the PG patients with improving disease at the time of discharge, 1 year after hospital discharge, one third of our 27 patients still had PG requiring readmission. In conclusion, none of the current therapies provide satisfying results in all of the patients, and our data indicate a long-standing unmet need for effective therapy for the unexpected course of PG.


Subject(s)
Cost of Illness , Glucocorticoids/therapeutic use , Leg Ulcer , Pyoderma Gangrenosum , Conservative Treatment/methods , Female , Humans , Leg Ulcer/etiology , Leg Ulcer/therapy , Length of Stay/statistics & numerical data , Male , Middle Aged , Patient Readmission/statistics & numerical data , Pyoderma Gangrenosum/complications , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/mortality , Pyoderma Gangrenosum/therapy , Retrospective Studies , Turkey/epidemiology
2.
Ann Dermatol Venereol ; 143(2): 108-17, 2016 Feb.
Article in French | MEDLINE | ID: mdl-26718901

ABSTRACT

BACKGROUND: Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic dermatosis for which accurate epidemiological data are limited and therapy remains a challenge. The primary study aim was to examine all cases of PG observed in our regional department over a 15-year period in order to describe the relevant characteristics and outcome under therapy. PATIENTS AND METHODS: The medical records of all patients with PG from 1997 to 2012 in the Marne department of France were studied retrospectively. Clinical and histological characteristics, comorbidities, therapeutic modalities and outcome were analysed. RESULTS: Forty-two patients were included (30 women, 12 men). A classical, ulcerative form was found in 39 cases and PG was multifocal in 28 cases. The number of lesions did not differ according to age or the presence of comorbidities. The most frequent first-line treatments were doxycycline (23 cases) and oral corticosteroids (15 cases), regardless of age, number of lesions or existence of comorbidities. Complete remission of PG was obtained in 38 cases (median time to remission: 3 months), with relapse occurring in 17 patients (median time to relapse: 12 months after treatment withdrawal). After a median follow-up of 46 months, 8 patients had died (median time to death: 26 months after treatment initiation). CONCLUSION: This is the first large French series of patients presenting PG and enabling determination of the annual incidence within the Marne department at around 4.6 cases/1000,000 inhabitants. Our study illustrates the value of first-line treatment with tetracycline, which merits confirmation by further prospective, controlled studies.


Subject(s)
Pyoderma Gangrenosum/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Doxycycline/therapeutic use , Female , France/epidemiology , Glucocorticoids/therapeutic use , Humans , Male , Middle Aged , Pyoderma Gangrenosum/mortality , Remission Induction , Retrospective Studies , Tetracycline/therapeutic use , Young Adult
3.
J Wound Ostomy Continence Nurs ; 42(1): 102-5, 2015.
Article in English | MEDLINE | ID: mdl-25549316

ABSTRACT

BACKGROUND: Extensive peristomal skin ulcer due to pyoderma gangrenosum is difficult to manage and causes significant morbidity. CASE: A 69-year-old man presented with a 10×7-cm painful peristomal skin necrosis during cancer chemotherapy for metastatic colon adenocarcinoma. The diagnosis of peristomal pyoderma gangrenosum was made on the basis of the presence of the skin necrosis with a well-defined, undermined, violaceous border. One month after the presentation along with daily cleansing and minimal debridement without immunosuppressive treatments, wound bed preparation was deemed sufficient for a split-thickness skin graft using negative pressure wound therapy for graft fixation. One month after the operation, the ulcer was completely healed and the patient could manage ostomy pouching independently. He died of cancer 5 months later; no recurrence of the ulcer was observed during this period. CONCLUSION: Peristomal pyoderma gangrenosum was successfully treated with skin grafting after local wound management. Negative pressure wound therapy was useful for skin graft fixation in the peristomal region.


Subject(s)
Colonic Neoplasms/complications , Ileostomy/adverse effects , Pyoderma Gangrenosum/surgery , Skin/pathology , Wound Healing , Aged , Colonic Neoplasms/mortality , Colonic Neoplasms/surgery , Humans , Male , Negative-Pressure Wound Therapy/statistics & numerical data , Pyoderma Gangrenosum/mortality , Pyoderma Gangrenosum/therapy , Skin Transplantation/statistics & numerical data
4.
J Invest Dermatol ; 132(9): 2166-70, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22534879

ABSTRACT

Pyoderma gangrenosum (PG) is an important disease with significant complications. The objectives of this study were to determine incidence and mortality of PG and strength of reported associations. A retrospective cohort study was completed using computerized medical records from the General Practice Research Database, a large representative UK database. Patients with PG and three groups of age-, sex-, and practice-matched controls--general population, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) controls--were included in the study. Incidence and mortality were determined and validation undertaken to inform diagnostic accuracy. In all there were 313 people with the median age of 59 (interquartile range 41-72) years, and of them 185 (59%) were female. The adjusted incidence rate standardized to European standard population was 0.63 (95% confidence interval (CI) 0.57-0.71) per 100,000 person-years. The risk of death was three times higher than that for general controls (adjusted hazard ratio=3.03, 95% CI 1.84-4.73, P<0.001), 72% higher than that for IBD controls (adjusted hazard ratio=1.72, 95% CI 1.17-2.59, P=0.013), with a borderline increase compared with RA controls (adjusted hazard ratio=1.55, 95% CI 1.01-2.37, P=0.045). Disease associations were present in 110 (33%) participants: IBD, n=67 (20.2%); RA, n=39 (11.8%); and hematological disorders, n=13 (3.9%). To our knowledge, there are no previous population-based studies of the epidemiology of PG, an important disease with significantly increased mortality.


Subject(s)
Pyoderma Gangrenosum/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Arthritis, Rheumatoid/epidemiology , Child , Databases, Factual/statistics & numerical data , Female , Hematologic Diseases/epidemiology , Humans , Incidence , Inflammatory Bowel Diseases/epidemiology , Male , Middle Aged , Pyoderma Gangrenosum/mortality , Retrospective Studies , Risk , United Kingdom/epidemiology , Young Adult
5.
J Dtsch Dermatol Ges ; 3(5): 334-42, 2005 May.
Article in English | MEDLINE | ID: mdl-16372799

ABSTRACT

Pyoderma gangrenosum (PG) is a non-infectious reactive neutrophilic dermatosis which typically starts with pustules which rapidly evolve to painful ulcers of variable size and depth with undermined violaceous borders. Since its first description in 1930, the pathogenesis of PG has remained elusive even as an ever-widening range of systemic diseases has been described in association with it. The diagnosis of PG is based on clinical and pathologic features and requires exclusion of other conditions that produce ulcerations, since misdiagnosis exposes patients to risks associated with treatment. Critical to proper management are correct diagnosis, identification and treatment of any underlying disorder, and the appropriate choice of topical and systemic therapy. PG has four distinctive clinical and histologic variants, and the specific clinical features of the lesion may provide a clue to the associated disease. The most common associated diseases are inflammatory bowel disease, rheumatological or hematological disease or malignancy. Although there is no single successful treatment for PG, certain type of PG lesions are recognized to respond more readily to accepted therapies than others. Local treatment may be sufficient for mild disease, while systemic immunosuppressive therapy is necessary for severe cases. The treatments with the best clinical evidence are oral or pulse intravenous corticosteroids, and cyclosporine. Surgical therapy is useful in selected cases in conjunction with immunosuppression. Wound stabilization is obtained only through control of the systemic and local inflammatory process. Emerging therapies include use of platelet-derived growth factor and cell culture grafts when re-epithelialization is slow, and the TNF-alpha blocking agent infliximab for refractory disease. Despite advances in therapy, the long-term outcome for patients with PG remains unpredictable, because relapses are common.


Subject(s)
Pyoderma Gangrenosum , Administration, Oral , Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/therapeutic use , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/therapeutic use , Biopsy , Cyclosporine/administration & dosage , Cyclosporine/therapeutic use , Dermatologic Agents/administration & dosage , Dermatologic Agents/therapeutic use , Diagnosis, Differential , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Infliximab , Injections, Intravenous , Prognosis , Pyoderma Gangrenosum/classification , Pyoderma Gangrenosum/complications , Pyoderma Gangrenosum/diagnosis , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/mortality , Pyoderma Gangrenosum/pathology , Pyoderma Gangrenosum/surgery , Recurrence , Skin/pathology , Skin Transplantation
6.
Rev. cuba. med. trop ; 53(3)sept.-dic. 2001.
Article in Spanish | CUMED | ID: cum-34367

ABSTRACT

Se presentó el caso de un paciente que desarrolló un pioderma gangrenoso vegetante que concomitaba con una insuficiencia renal aguda, esto lo llevó a un estado de gravedad extrema. El paciente recibió tratamiento inicialmente con antibióticos sistémicos por considerarse el cuadro como una piodermitis, pero no se obtuvo una respuesta satisfactoria. Después fue tratado con Levamizol y alfa interferón, y se logró con este tratamiento mejoría de su estado general y de sus lesiones cutáneas. Se realizó entonces exéresis quirúrgica, con autoinjerto de las lesiones de la cara y el pene, con buenos resultados. Las lesiones pioderma gangrenoso fueron recidivantes, se trataron con prednisona y se obtuvo una rápida resolución de las lesiones en cada ocasión que se presentaron(AU)


Subject(s)
Humans , Male , Pyoderma Gangrenosum/surgery , Pyoderma Gangrenosum/drug therapy , Pyoderma Gangrenosum/mortality , Renal Insufficiency , Levamisole/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...